Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

InflaRx Shares Plunge After Disappointing Results On Vilobelimab In Critically Ill COVID-19 Patients

Published 31/03/2022, 18:18
© Reuters.  InflaRx Shares Plunge After Disappointing Results On Vilobelimab In Critically Ill COVID-19 Patients
IFRX
-

  • InflaRx N.V. (NASDAQ: IFRX) announced topline data from Phase 3 part of Phase 2/3 PANAMO study of vilobelimab in critically ill COVID-19 patients.
  • Vilobelimab in mechanically ventilated COVID-19 patients showed a relative reduction in 28-day all-cause mortality of 23.9% (vilobelimab 31.7% versus placebo 41.6%), which was not statistically significant (p=0.094).
  • At the recommendation of regulatory authorities, during the trial, the Company changed the statistical analysis method for the primary endpoint.
  • The original protocol specified a non-stratified Cox regression analysis that would have resulted in a p-value of 0.027 (statistically significant), the Company said.
  • Also Read: FDA Issues Corrected Advice To InflaRx's Vilobelimab Study In Skin Disease.
  • A pre-specified analysis of patients from Western European countries (n=209) showed a relative reduction in 28-day all-cause mortality of 43% (vilobelimab 21.2% versus placebo 37.2%).
  • The Company plans to discuss the data with regulatory authorities to determine potential next steps in developing vilobelimab for this indication.
  • Sixty-day all-cause mortality, a key secondary endpoint, showed a continued reduction of mortality in the vilobelimab arm (36.5% vilobelimab versus 47.2% placebo.
  • In this study, vilobelimab appeared to be safe and well-tolerated.
  • Price Action: IFRX shares are down 16.8% at $1.99 during the market session on the last check Thursday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.